Top of page

Support from healthcare and pharmaceutical companies

Please refer to our policy to understand how we work with healthcare and pharmaceutical companies. Acceptance of donations does not mean that we endorse their products and under no circumstances can these companies influence our strategic direction, activities or the content of the information and support we provide to people affected by lymphoma.

Funding Received in 2023*

  • Roche £15,000
    • Contributed towards our helpline, Information Provisions and Live your Life campaign. 
  • Gilead £50,698
    • Contributed towards our Peer Support Network and our new Preparing for Treatment project. 
  • Takeda £15,000
    • Contributed towards our National Conference and publications including Lymphoma Matters magazine. 
  • Sobi £15,000
    • Contributed towards our Helpline, Information Provisions and Live your Life campaign.
  • Kyowa Kirin £10,000
    • Contributed towards our Healthcare Professional project lead.
  • BMS Celegne £10,000
    • Contributed towards our Helpline and Information Provisions.
  • AbbVie £10,000
    • Contributed towards our Helpline and publications including Lymphoma Matters magazine.
  • BeiGene £24,000
    • Contributed towards our Lymphoma Management Course.
  • Incyte Biosciences £11,583
    • Contributed towards our publications including Lymphoma Matters.
  • Recordati Rare Diseases £5,000
    • Contributed towards our new Healthcare professional project. 
  • Serb Pharmaceuticals £10,000
    • Contributed towards our Helpline and Live your Life self-management course. 

*Updated February 2024

Funding Received in 2022*

  • Incyte Biosciences UK Ltd £22,750
    • Contributed towards our publications, Lymphoma Matters magazine, education programmes for people affected by lymphoma, health inequalities project, Lymphoma Management course. 
    • Workshop participation.
  • Kyowa Kirin £12,150
    • Contributed towards TrialsLink, webpages, health inequalities project, Lymphoma Management course and our information and support services.
  • Takeda £16,000
    • Contributed towards our Lymphoma Matters magazine, health inequalities project, publications and Lymphoma Management course. 
  • Roche £26,000
    • Contributed towards our digital events, TrialsLink and Lymphoma Management course.
  • AbbVie £10,000
    • Contributed towards our education programmes for people affected by lymphoma.
  • Gilead £45,870
    • Contributed towards health inequalities project, publications and Lymphoma Management course. 
  • Eli Lilly £11,000
    • Contributed towards our publications, Lymphoma Matters magazine and Lymphoma Management course.
  • Janssen £12,500
    • Contributed towards our publications and education programmes for people affected by lymphoma. 
  • BMS £11,000
    • Contributed towards our publications, Lymmphoma Matters magazine and Lymphoma Management course.
  • AstraZeneca £11,000
    • Contributed towards our publications, website mobile optimisation and Lymphoma Management course.
  • Novartis £1000
    • Contributed towards Lymphoma Management course.
  • Pfizer £300
    • Workshop participation. 

*Updated March 2023

Funding Received in 2021*

  • Janssen £8,000
    • Contributed towards our digital patient services, Live your Life workshops and publications.
  • AstraZeneca £40,000
    • Contributed towards health inequalities project and digital events.
  • Takeda £21,000
    • Contributed towards education and training, publications, Lymphoma Management course and webpages.
  • Gilead £1,000
    • Contributed towards Lymphoma Management course.
  • AbbVie £12,000 
    • Contributed towards our publications, Lymphoma Management magazine and Live your Life workshops.
  • Roche £22,000
    • Contributed towards our digital patient services, Lymphoma Management course and nurses training.
  • Incyte Biosciences UK Ltd £22,000
    • Contributed towazards educationa nd training, publications, Lymphoma Management course, nurses training and webpages.
  • Bristol Myers Squibb-Celgene £21,000
    • Contributed towards our education and training, publications, Lymphoma Matters magazine, Lymphoma Management course and TrialsLink.
  • Kyowa Kirin £16,800
    • Contributed towards education and training, publications and Lymphoma Matters magazine.
  • Recordati Rare Diseases £5,800
    • Contributed towards digital patient support and nurses training.

*Updated March 2023

Funding Received in 2020*

  • Gilead £41,339
  • AbbVie Ltd £23,885
  • AstraZeneca £37,000
  • Kyowa Kirin £14,000
  • Bristol Myers Squibb £35,000
  • Roche £20,000
  • Takeda £32,000
  • Janssen £45,000
  • Novartis £17,723
  • Recordati Rare Diseases UK £5,000

*Updated January 2021

Funding received in 2019*

  • 4SC AG £750
  • AbbVie Ltd  £10,000
  • AstraZeneca £8,394
  • Bristol-Myers Squibb Pharmaceuticals Ltd £5,000
  • Celgene £20,000
  • Gilead Sciences Ltd £36,862
  • Janssen-Cilag Ltd £15,000
  • Kyowa Kirin Ltd £15,500
  • Mallinckrodt Pharmaceuticals £3,000
  • Novartis £10,410
  • Proton Partners International Ltd £750
  • Recordati Rare Diseases previously Orphan Europe £3,000
  • Roche Products Ltd £12,000
  • Takeda UK Ltd £27,750

*Updated Jan 2020

Funding received in 2018

  • AbbVie Ltd £13,000
  • Alliance Medical £1,200
  • Bayer AG £3,000
  • Bristol-Myers Squibb Pharmaceuticals Ltd £10,000
  • Celgene Ltd £15,000
  • Gilead Sciences Ltd £30,775
  • Janssen-Cilag Ltd  £10,950
  • Proton Therapy UK Ltd £500
  • Roche Products Ltd £13,500
  • Sandoz £5,000
  • Servier Laboratories Ltd  £1,500
  • Takeda UK Ltd £39,420